Home/Filings/4/0000899243-22-006538
4//SEC Filing

Nosenzo John 4

Accession 0000899243-22-006538

CIK 0001665988other

Filed

Feb 14, 7:00 PM ET

Accepted

Feb 15, 9:17 PM ET

Size

9.2 KB

Accession

0000899243-22-006538

Insider Transaction Report

Form 4
Period: 2022-02-11
Nosenzo John
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2022-02-111,4700 total
    Class A Common Stock (1,470 underlying)
  • Sale

    Class A Common Stock

    2022-02-14$11.99/sh534$6,40143,370 total
  • Exercise/Conversion

    Class A Common Stock

    2022-02-11+1,47043,904 total
Footnotes (4)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
  • [F2]Reflects shares sold to cover taxes upon the vesting of restricted stock units on February 11, 2022 pursuant to a standing 10b5-1 instruction.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.87 to $11.99, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F4]The restricted stock units vested on February 11, 2022.

Issuer

Bioventus Inc.

CIK 0001665988

Entity typeother

Related Parties

1
  • filerCIK 0001835973

Filing Metadata

Form type
4
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 9:17 PM ET
Size
9.2 KB